Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...
SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...
It’s among the most common cancers affecting older men. But a diagnosis today isn’t always what it seems. By David Dodge An estimated one in eight men will be diagnosed with prostate cancer in their ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery—the ...
Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...
Although the Endocrine Society guidelines recommend TRT for men with testosterone levels ≤ 300 ng/dL in two morning samples, a primary concern is its potential to exacerbate prostate-related ...
TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, ...
Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy The 2022 AUA/ASTRO guidelines recommend 18-36 months of androgen deprivation therapy (ADT) ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Men with aggressive prostate cancer who were being treated with a groundbreaking drug have been told the therapy is no longer available at public hospitals. Lutetium PSMA was being compounded locally, ...
SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone ...
One in eight men in the United States will be diagnosed with prostate cancer in their lifetime. The prostate is a gland in the male reproductive system that produces seminal fluid. Prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback